InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Cover Story

  • The fine line between abuse and fair use at the PTAB

    Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system

Features

  • EPO rules on plant patents cases

    The EPO’s Enlarged Board of Appeal has held that patents on plants produced by essentially biological process are not excluded from patentability. But Claudia E Unsin and Joseph P Taormino say this is not the end of the debate over the use of patented material by plant breeders

  • Battling trade mark piracy in Cuba

    With diplomatic relations between the US and Cuba slowly being restored, many US companies are keen to register their trade marks in Cuba. But, says Erica Gould, they need to watch out for pirates who have got there first

  • US software patents – Obtainable, enforceable, and as important as ever

    Rumours of the death of software patents are greatly exaggerated, say Elliot Cook, Brandon Bludau and Darren Jiron. Various software-based inventions were patented by the USPTO at rates even higher in 2014 than previous years while many types of software patents are being upheld by courts

  • What should influence your decision to opt-out of the UPC?

    David Wilson, Rachel Montagnon and Christopher Sharp discuss European, Unitary and national patent registration strategies in the context of the option to opt-out of the Unified Patent Court

  • Hague gives teeth to provisional rights

    Publication of design patent applications under the Hague Agreement for the Registration of Industrial Designs increases the value of provisional rights in the United States, as Brent M Dougal explains

  • IPOS develops patent services for businesses

    Through its IPOS International (IPOS-I) initiative, the IP Office of Singapore (IPOS) provides IP-related services to businesses. IPOS-I, which launched in January, offers patent-related services such as prior art searches, patent landscaping and analytics. Peter Leung reports

  • Time for a new tool in EPC’s box?

    Ylva Skoglösa, Annika Unge Reis and Isabel Cantallops Fiol of Valea ask what the future holds for second medical use claims in Europe

  • The history and future of induced infringement liability

    On May 26, the US Supreme Court held in Commil USA v Cisco Systems that a defendant’s good-faith belief that a patent is invalid is not a defence to induced infringement under 35 USC § 271(b). What is the history of the good-faith defence to induced infringement, and how should rights holders prepare going forward? Dalila Argaez Wendlandt and Peter Walkingshaw explore the issues

IP Clinic

Diary

  • Utynam’s Heirs

    A monthly column devoted to IP curiosities and controversies, named in honour of John of Utynam

Country Updates

profile

Managing IP

ManagingIP

ManagingIP profile

.@JPO_JPN interim decision on handling product-by-process claims following SC judgments http://t.co/lhItpjgPSC More on our site soon #patent

Jul 7 2015 03:28 ·  reply ·  retweet ·  favourite
ManagingIP profile

.@NetNamesDomains has filed a competition complaint with the European Commission over the .sucks "uneven pricing structure". More info soon

Jul 7 2015 03:23 ·  reply ·  retweet ·  favourite
ManagingIP profile

On the blog, James Nurton brings four tidbits from the recent #ipinasia forum in Munich http://t.co/sNNA0W97cT http://t.co/IAZcOiixZ0

Jul 7 2015 02:16 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


INTA Daily News 2015

Read this year's INTA Daily News - published daily by Managing IP direct from the INTA Annual Meeting in San Diego


June 2015

The fine line between abuse and fair use at the PTAB

Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system



Most read articles

Supplements